7.45
Ginkgo Bioworks Holdings Inc stock is traded at $7.45, with a volume of 575.42K.
It is up +1.22% in the last 24 hours and down -27.32% over the past month.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
See More
Previous Close:
$7.36
Open:
$7.54
24h Volume:
575.42K
Relative Volume:
0.48
Market Cap:
$486.67M
Revenue:
$141.31M
Net Income/Loss:
$-297.87M
P/E Ratio:
-1.3813
EPS:
-5.3933
Net Cash Flow:
$-168.20M
1W Performance:
-1.32%
1M Performance:
-27.32%
6M Performance:
-23.27%
1Y Performance:
-46.63%
Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile
Name
Ginkgo Bioworks Holdings Inc
Sector
Industry
Phone
(877) 442-5362
Address
27 DRYDOCK AVENUE, BOSTON
Compare DNA vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
DNA
Ginkgo Bioworks Holdings Inc
|
7.45 | 480.79M | 141.31M | -297.87M | -168.20M | -5.3933 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-15-24 | Downgrade | BTIG Research | Neutral → Sell |
| May-10-24 | Downgrade | William Blair | Mkt Perform → Underperform |
| Nov-14-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-09-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-02-23 | Downgrade | Goldman | Neutral → Sell |
| May-11-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-29-22 | Initiated | Berenberg | Buy |
| Oct-04-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-18-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-02-22 | Resumed | Cowen | Outperform |
| Feb-23-22 | Initiated | Goldman | Neutral |
| Feb-01-22 | Initiated | BofA Securities | Neutral |
| Jan-28-22 | Initiated | BofA Securities | Buy |
| Jan-07-22 | Initiated | BTIG Research | Buy |
| Nov-29-21 | Initiated | Jefferies | Buy |
| Oct-13-21 | Initiated | Raymond James | Outperform |
| Oct-12-21 | Initiated | William Blair | Outperform |
| Sep-20-21 | Initiated | HSBC Securities | Buy |
View All
Ginkgo Bioworks Holdings Inc Stock (DNA) Latest News
Ginkgo Bioworks Holdings Inc (DNA) Balance Sheet - TradingKey
DNA|Ginkgo Bioworks Holdings Inc|Price:7.445|Chg%:+0.085 - TradingKey
Ginkgo Bioworks Holdings Inc (DNA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ginkgo Bioworks Holdings Inc (DNA) Income Statement - TradingKey
DNA|Ginkgo Bioworks Holdings Inc|Price:7.761| - TradingKey
ETFs Investing in Ginkgo Bioworks Holdings, Inc. Class A Stocks - TradingView
Ginkgo Bioworks Holdings Inc (DNA) Cash Flow - TradingKey
Ginkgo Bioworks Holdings Inc (DNA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
DNA|Ginkgo Bioworks Holdings Inc|Price:7.360|Chg%:-0.575 - TradingKey
Responsive Playbooks and the DNA Inflection - Stock Traders Daily
Ginkgo Regains Compliance with NYSE Minimum Bid Price Requiremen - GuruFocus
Ginkgo Bioworks Holdings Inc (DNA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Ginkgo CEO Jason Kelly: Block U.S. Investment in Chinese Biotech Before Drug Discovery Moves Entirely Offshore - finance.biggo.com
Biotech firm Ginkgo in talks with SPAC for over $20b deal - The Financial Express
Ginkgo Bioworks (NYSE: DNA) CFO logs RSU vesting and tax sell-to-cover - Stock Titan
Ginkgo Bioworks (DNA) 10K Form and Latest SEC Filings 2026 - MarketBeat
Form 144 Ginkgo Bioworks Holdings For: 17 July By Investing.com - Investing.com Nigeria
Ginkgo Bioworks (NYSE: DNA) insider Steve Coen plans Class A stock sale - Stock Titan
Ginkgo Bioworks (DNA) Slides 7.89% as Market Sentiment Turns CautiousTriple EMA - dars.gov.et
Synthetic Biology Market Set for Strong Expansion | Ginkgo - openPR.com
Ginkgo Bioworks Holdings' Stock Sinks To US$9.07, But Insiders Sold Even Lower - simplywall.st
Ginkgo Bioworks : Q1 2026 Results Presentation - marketscreener.com
DNAGinkgo Bioworks Holdings Inc Options - Finviz
Ginkgo Bioworks reports Q1 revenue decline, reaffirms cash burn - Investing.com
Ginkgo Bioworks Holdings Inc (DNA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Most Volatile Stocks in the US (July 2026) - Investing.com
Ginkgo Bioworks Holdings Inc Warrant 2021-01.08.26 on Ginkgo Bioworks -A Financial Disclosures & SEC Filings - TradingView
How Western Biotechs Are Navigating The China Challenge - insights.citeline.com
Understanding the Setup: (DNA) and Scalable Risk - Stock Traders Daily
Ginkgo Bioworks (DNA) Holds Near $10.21 as Stock Consolidates in Tight RangeIron Condor Alert - dars.gov.et
Ginkgo Bioworks Holdings, Inc.(NYSE:DNA) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Ginkgo Bioworks Holdings, Inc.(NYSE: DNA) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Ginkgo Bioworks Holdings, Inc.(NYSE:DNA) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Palantir's Bold Biosecurity Opportunity Could Be Bigger Than Investors Think - The Motley Fool
Ginkgo Bioworks (DNA) Q1 2026 Earnings: EPS Misses Estimates, Stock Surges Over 7%Buyback Announcement Report - dars.gov.et
Enterprise value to revenue forward of Ginkgo Bioworks Holdings, Inc. – NYSE:DNA - TradingView
Price to earnings forward of Ginkgo Bioworks Holdings, Inc. – NYSE:DNA - TradingView
Enterprise value to EBIT forward of Ginkgo Bioworks Holdings, Inc. – NYSE:DNA - TradingView
Enterprise value to EBITDA forward of Ginkgo Bioworks Holdings, Inc. – NYSE:DNA - TradingView
Price to sales forward of Ginkgo Bioworks Holdings, Inc. – NYSE:DNA - TradingView
Ginkgo Bioworks (DNA) Rallies 6.27% as Biotech Sector Shows Renewed StrengthInitial Balance - dars.gov.et
Ginkgo Bioworks Holdings, Inc. Class A Actuals & Estimates (NYSE:DNA) - TradingView
9L40 Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Ginkgo Bioworks Holdings Inc. – OTC:DNABW - TradingView
Price to earnings forward of Ginkgo Bioworks Holdings Inc. – OTC:DNABW - TradingView
Enterprise value to EBITDA forward of Ginkgo Bioworks Holdings Inc. – OTC:DNABW - TradingView
Price to book forward of Ginkgo Bioworks Holdings Inc. – OTC:DNABW - TradingView
DNA Forecast — Price Target — Prediction for 2027 - TradingView
Ginkgo Bioworks Holdings Inc (DNA) Valuation: PE, PB & Fair Value Analysis - TradingKey
The Technical Signals Behind (DNA) That Institutions Follow - Stock Traders Daily
DNA Technical Analysis & Stock Price Forecast - Intellectia AI
Ginkgo Bioworks Holdings Inc Stock (DNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):